Anti-TIA1 Antibody, clone 2I11 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Cytotoxic granule associated RNA binding protein TIA1 (UniProt: P31483; also known as Nucleolysin TIA-1 isoform p40, RNA-binding protein TIA-1, T-cell-restricted intracellular antigen-1, p40-TIA-1, TIA-1) is encoded by the TIA1 gene (Gene ID: 7072) in human. TIA1 is a member of a RNA-binding protein family and characterized by its role in post-transcriptional regulation of gene expression, particularly during cellular stress responses. It is a multifunctional protein and possesses nucleolytic activity against cytotoxic lymphocyte (CTL) target cells. It has been suggested that this protein may be involved in the induction of apoptosis as it preferentially recognizes poly(A) homopolymers and induces DNA fragmentation in CTL targets. The major granule-associated species is a 15-kDa protein that is thought to be derived from the carboxyl terminus of the 40-kDa product by proteolytic processing. Structurally, TIA1 contains three RNA recognition motifs (RRMs) and a prion-like domain, which facilitate its interaction with various mRNAs, including those involved in stress granule formation. It is predominantly expressed in heart, small intestine, kidney, liver, lung, skeletal muscle, testes, pancreas, and ovary. TIA1 is localized in the nucleus and accumultaes in cytoplasm, where it localizes to stress granules and processing bodies, acting as a key regulator of mRNA stability and translation, especially under stress conditions such as heat shock or oxidative stress. Alternative splicing resulting in three different isoforms of this gene product has been described in the literature. Dysregulation of TIA1 has been implicated in various diseases, including neurodegenerative disorders like amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), where its abnormal aggregation is associated with pathological protein inclusions. Additionally, TIA1′s involvement in regulating p53 mRNA localization underscores its critical role in cell cycle control and apoptosis. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Matsumoto. G., et al. (2020). Cell Reports. 32(3); 107901).

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

KLH-conjugated linear peptide corresponding to 16 amino acids from the C-terminal region of human TIA1.

Quality Control Testing

Evaluated by Western Blotting in U-2 OS cell lysate.

Western Blotting Analysis: A 1:50,000 dilution of this antibody detected TIA1 in U-2 OS cell lysate.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected TIA1 in lysates from NK-92 cells and Jurkat cells.

Affinity Binding Assay: A representative lot of this antibody bound TIA1 peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.

Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected TIA1 in Jurkat cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 2I11 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects TIA1. It targets an epitope within 16 amino acids from the C-terminal region.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.